Diabetic Kidney Disease Market Report 2026

Diabetic Kidney Disease Market Overview

• Diabetic Kidney Disease market size has reached to $2.8 billion in 2025 • Expected to grow to $3.76 billion in 2030 at a compound annual growth rate (CAGR) of 6.1% • Growth Driver: The Soaring Prevalence Of Chronic Kidney Disease Propelling Growth In The Diabetic Kidney Disease Market • Market Trend: AI-Powered Diagnostics Revolutionize Early Risk Assessment And Patient Management • North America was the largest region in 2025.

What Is Covered Under Diabetic Kidney Disease Market?

Diabetic kidney disease refers to a type of renal disease driven by complications of diabetes that occurs when high levels of blood sugar cause damage to the kidneys. The blood vessels in the kidneys can become affected by high blood glucose, which ultimately reduces their functionality. The main types of diabetic kidney disease are type 1 diabetes and type 2 diabetes. Type 1 diabetes refers to a chronic autoimmune condition in which the pancreas produces little or no insulin, leading to high blood sugar levels that cause harm to the nephrons and renal blood vessels and requiring daily insulin injections to manage blood sugar levels. They are treated by angiotensin receptor blockers (ARBs), angiotensin-converting enzyme (ACE) inhibitors, antioxidant inflammation modulators, calcium channel blockers, and other treatments in medical facilities including hospitals, homecare, specialty centers, and others.

What Is The Diabetic Kidney Disease Market Growth Forecast?

The diabetic kidney disease market size is expected to see strong growth in the next few years. It will grow to $3.76 billion in 2030 at a compound annual growth rate (CAGR) of 6.1%. The growth in the forecast period can be attributed to advancements in renal protective drugs, increasing early diagnosis initiatives, growing chronic kidney disease burden, expansion of specialty nephrology care, focus on personalized treatment strategies. Major trends in the forecast period include growing adoption of early renal screening, increased use of renoprotective drug therapies, expansion of combination treatment approaches, rising focus on disease progression delay, integration of multidisciplinary care models.

Global Diabetic Kidney Disease Market Segmentation

1) By Type: Type 1 Diabetes, Type 2 Diabetes 2) By Treatment: Angiotensin Receptor Blockers (Arbs), Angiotensin-Converting Enzyme (Ace) Inhibitors, Antioxidant Inflammation Modulator, Calcium Channel Blockers, Other Treatments 3) By End User: Hospitals, Homecare, Specialty Centers, Other End Users Subsegments: 1) By Type 1 Diabetes: Autoimmune-Related Diabetic Kidney Disease, Early-Onset Diabetic Kidney Disease 2) By Type 2 Diabetes: Obesity-Related Diabetic Kidney Disease, Late-Onset Diabetic Kidney Disease

What Is The Driver Of The Diabetic Kidney Disease Market?

The rising prevalence of chronic kidney disease is expected to propel the growth of the diabetic kidney disease market. Chronic kidney disease (CKD) refers to a long-term condition that results in the loss of kidney function over time causing a number of complications such as high blood pressure, anemia, and bone diseases. The treatment of chronic kidney diseases requires diagnostic and treatment options, ultimately fueling the growth of the diabetic kidney disease market. For instance, in June 2023, according to the Kidney Research UK, a UK-a prominent charity, chronic kidney disease (CKD) affects around 7.2 million people in the United Kingdom, accounting for more than 10% of the population. Among these, 3.25 million are in the most severe stages of the disease, while around 3.9 million are in the early stages, which are frequently untreated and asymptomatic. According to projections, the overall number of people with chronic renal disease in the United Kingdom could reach 7.61 million by 2033. Therefore, the rising prevalence of chronic kidney disease is driving the growth of the diabetic kidney disease industry going forward.

Key Players In The Global Diabetic Kidney Disease Market

Major companies operating in the diabetic kidney disease market are AstraZeneca plc, Pfizer Inc., Novartis AG, Bayer AG, Sanofi SA, Teva Pharmaceutical Industries Ltd., Bristol-Myers Squibb Company, Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Ltd., Fresenius SE & Co. KGaA, F. Hoffmann-La Roche AG, Abbott Laboratories, Reata Pharmaceuticals Inc., Merck & Co., Mitsubishi Tanabe Pharma Corporation, Johnson & Johnson pvt. Ltd., Eli Lilly and Company, GlaxoSmithKline plc, AbbVie Inc., Boehringer Ingelheim International GmbH, Chugai Pharmaceutical Co. Ltd., Daiichi Sankyo Company Limited

Global Diabetic Kidney Disease Market Trends and Insights

Major companies operating in the diabetic kidney disease market are focusing on incorporating advanced solutions such as artificial intelligence (AI)-enabled prognostic platforms to enhance early risk stratification, personalized disease management, and long-term patient outcomes. Artificial intelligence (AI)-enabled prognostic platforms are diagnostic tools that combine blood-based biomarker measurements with machine-learning algorithms to predict the likelihood of progressive kidney decline, enabling capabilities such as risk-score generation, patient stratification, and early clinical intervention planning. For instance, in June 2023, Renalytix plc, a UK-based diagnostics company, received U.S. Food and Drug Administration (FDA) De Novo marketing authorization for KidneyIntelX.dkd, an AI-driven prognostic platform designed to assess the risk of significant kidney function decline in adults with type 2 diabetes and early-stage chronic kidney disease. The platform features biomarker-integrated machine-learning algorithms, cloud-based workflow integration, and stratified risk reporting. KidneyIntelX.dkd improves clinical decision-making, supports targeted monitoring strategies, and enhances proactive care planning

What Are Latest Mergers And Acquisitions In The Diabetic Kidney Disease Market?

In January 2023, AstraZeneca, a UK-based biotechnology, and pharmaceutical company, acquired Cincor Pharma Inc., for an undisclosed amount. This acquisition will bolster AstraZeneca’s cardiorenal pipeline by adding CinCor’s candidate drug, baxdrostat (CIN-107), an aldosterone synthase inhibitor (ASI) for blood pressure lowering in treatment-resistant hypertension. CinCor Pharma Inc. is a US-based biopharmaceutical company specializing in the development of drugs for the management of kidney disease.

Regional Outlook

North America was the largest region in the diabetic kidney disease market in 2025. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Diabetic Kidney Disease Market?

The diabetic kidney disease market includes revenues earned by entities by providing diabetic kidney disease treatments for kidney stones, kidney infection, polycystic kidney disease, and kidney cysts. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Diabetic Kidney Disease Market Report 2026?

The diabetic kidney disease market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the diabetic kidney disease industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.